Decrease in TSH Receptor Autoantibodies during Antithyroid Treatment: Relationship with a Long Noncoding Heg RNA and...

Area of Science:

• Endocrinology
• Molecular Biology
• Immunology

Background:

• Graves' disease is an autoimmune disorder characterized by elevated TSH receptor autoantibodies (TRAb).
• Previous studies indicated a negative correlation between long noncoding RNA Heg and TRAb in untreated patients.
• The role of gene expression, specifically Cdk1, in relation to TRAb levels remained unclear.

Purpose of the Study:

• To investigate the relationship between Cdk1 gene expression and TRAb concentrations in Graves' disease.
• To explore the influence of Heg RNA and Cdk1 mRNA on TRAb levels during disease progression and treatment.
• To elucidate the distinct mechanisms by which Heg RNA and Cdk1 mRNA may affect TRAb.

Main Methods:

• Analysis of Heg RNA and Cdk1 mRNA expression in mononuclear cells from Graves' disease patients and controls.
• Correlation analysis between RNA levels and TRAb concentrations in untreated and treated patients.
• Comparison of RNA levels before and after antithyroid drug treatment.

Main Results:

• Cdk1 gene expression in mononuclear cells is positively associated with TRAb levels in untreated Graves' disease patients.
• Heg RNA levels remain unchanged during antithyroid drug treatment, while Cdk1 mRNA significantly decreases.
• Cdk1 mRNA levels in treated patients fall below those observed in normal subjects.

Conclusions:

• Both Heg RNA and Cdk1 mRNA play a role in modulating TSH receptor autoantibodies in Graves' disease.
• Heg RNA and Cdk1 mRNA appear to influence TRAb levels through distinct mechanisms.
• Cdk1, involved in cell cycle regulation, shows a significant decrease during treatment, suggesting its involvement in TRAb reduction.